Benzonatate, a non-narcotic antitussive agent, is 2, 5, 8, 11,
14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a
molecular weight of 603.7.
Structure Image
Benzonatate Capsules, USP contain 100 mg or 200 mg of benzonatate, USP.
Benzonatate Capsules also contain: D and C Yellow No. 10, gelatin, glycerin,
methylparaben sodium and propylparaben sodium.
CLINICAL PHARMACOLOGY SECTION
CLINICAL PHARMACOLOGY
Benzonatate acts peripherally by anesthetizing the stretch
receptors located in the respiratory passages, lungs, and pleura by dampening
their activity and thereby reducing the cough reflex at its source. It begins to
act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate
has no inhibitory effect on the respiratory center in recommended dosage.
INDICATIONS & USAGE SECTION
INDICATIONS AND USAGE
Benzonatate acts peripherally by anesthetizing the stretch
receptors located in the respiratory passages, lungs, and pleura by dampening
their activity and thereby reducing the cough reflex at its source. It begins to
act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate
has no inhibitory effect on the respiratory center in recommended dosage.
CONTRAINDICATIONS SECTION
CONTRAINDICATIONS
Hypersensitivity to benzonatate or related compounds.
WARNINGS SECTION
WARNINGS
Severe hypersensitivity reactions (including bronchospasm,
laryngospasm and cardiovascular collapse) have been reported which are possibly
related to local anesthesia from sucking or chewing the capsule instead of
swallowing it. Severe reactions have required intervention with vasopressor
agents and supportive measures.
PRECAUTIONS SECTION
PRECAUTIONS
Benzonatate is chemically related to anesthetic agents of the
para-aminobenzoic acid class (e.g., procaine; tetracaine) and has been
associated with adverse CNS effects possibly related to a prior sensitivity to
related agents or interaction with concomitant medication.
Information for the Patient
Release of benzonatate from the capsule in the mouth can produce a temporary
local anesthesia of the oral mucosa and choking could occur. Therefore, the
capsules should be swallowed without chewing.
Usage in Pregnancy: Pregnancy Category C. Animal reproduction studies have not been
conducted with benzonatate. It is also not known whether benzonatate can cause
fetal harm when administered to a pregnant woman or can affect reproduction
capacity. Benzonatate should be given to a pregnant woman only if clearly
needed.
Nursing Mothers: It is not known whether this
drug is excreted in human milk. Because many drugs are excreted in human milk,
caution should be exercised when benzonatate is administered to a nursing
woman.
Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenicity,
mutagenicity, and reproduction studies have not been conducted with
benzonatate.
Pediatric Use: Safety and effectiveness in
children below the age of 10 has not been established.
ADVERSE REACTIONS SECTION
ADVERSE REACTIONS
Potential Adverse Reactions to benzonatate may include:
Hypersensitivity reactions including bronchospasm, laryngospasm,
cardiovascular collapse possibly related to local anesthesia from chewing or
sucking the capsule.
Other: nasal congestion; sensation of burning in the
eyes; vague “chilly” sensation; numbness of the chest; hypersensitivity.
Rare instances of deliberate or accidental overdose have resulted in death.
OVERDOSAGE SECTION
OVERDOSAGE
Overdose may result in death.
The drug is chemically related to tetracaine and other topical anesthetics
and shares various aspects of their pharmacology and toxicology. Drugs of this
type are generally well absorbed after ingestion.
Signs and Symptoms: If capsules are chewed or
dissolved in the mouth, oropharyngeal anesthesia will develop rapidly. CNS
stimulation may cause restlessness and tremors, which may proceed to clonic
convulsions followed by profound CNS depression.
Treatment: Evacuate gastric contents and
administer copious amounts of activated charcoal slurry. Even in the conscious
patient, cough and gag refluxes may be so depressed as to necessitate special
attention to protection against aspiration of gastric contents and orally
administered materials. Convulsions should be treated with a short-acting
barbiturates given intravenously and carefully titrated for the smallest
effective dosage. Intensive support of respiration and cardiovascular-renal
function is an essential feature of the treatment of severe intoxication from
overdosage.
Do not use CNS stimulants.
DOSAGE & ADMINISTRATION SECTION
DOSAGE AND ADMINISTRATION
Adults and children over 10:
Usual dose is one 100 mg or 200 mg capsules t.i.d. as required. If necessary,
up to 600 mg daily may be given.
HOW SUPPLIED SECTION
HOW SUPPLIED
Benzonatate Capsules, USP are available as:
Soft gelatin capsules, 100 mg (oval, yellow); bottle of 100
Imprint: A1.
NDC# 65162-536-10
Soft gelatin capsules, 100 mg (oval, yellow); bottle of 500
Imprint: A1.
NDC# 65162-536-50
Soft gelatin capsules, 200 mg (oblong, yellow); bottle of 100
Imprint: A2.
NDC# 65162-537-10
Store at 25°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Dispense
in tight, light-resistant container as defined in the USP.
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.